BioNTech SE (BNTX)
NASDAQ: BNTX · IEX Real-Time Price · USD
86.17
-0.23 (-0.27%)
At close: Apr 18, 2024, 4:00 PM
86.20
+0.03 (0.03%)
After-hours: Apr 18, 2024, 7:45 PM EDT
BioNTech SE Revenue
In the year 2023, BioNTech SE had annual revenue of $4.24B, a decrease of -76.96%. Revenue in the quarter ending December 31, 2023 was $1.64B, a -63.89% decrease year-over-year.
Revenue (ttm)
$4.24B
Revenue Growth
-76.96%
P/S Ratio
4.83
Revenue / Employee
$691,885
Employees
6,133
Market Cap
20.48B USD
Revenue Chart
* The company reports in EUR currency but revenue data is shown in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 4.24B | -14.17B | -76.96% |
| Dec 31, 2022 | 18.42B | -3.15B | -14.60% |
| Dec 31, 2021 | 21.56B | 20.98B | 3,566.36% |
| Dec 31, 2020 | 588.17M | 466.15M | 382.02% |
| Dec 31, 2019 | 122.02M | -24.62M | -16.79% |
| Dec 31, 2018 | 146.64M | 72.72M | 98.37% |
| Dec 31, 2017 | 73.92M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Molina Healthcare | 34.07B |
| Baxter International | 14.81B |
| ICON PLC | 8.12B |
| Zimmer Biomet Holdings | 7.39B |
| STERIS | 5.41B |
| Illumina | 4.50B |
| Align Technology | 3.86B |
| Genmab | 2.44B |
BNTX News
- 11 days ago - Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer - GlobeNewsWire
- 24 days ago - BioNTech gets US agency notice over default on COVID vaccine royalties - Reuters
- 4 weeks ago - BioNTech Earnings Fall Short of Estimates. The Stock Is Down. - Barrons
- 4 weeks ago - BioNTech Q4 earnings: COVID franchise to remain a notable cash contributor in 2024 - Invezz
- 4 weeks ago - BioNTech's stock sinks after earnings fall below expectations, hurt by writedowns of vaccine inventory - Market Watch
- 4 weeks ago - After earnings plunge, BioNTech pins hopes on cancer drug launches - Reuters
- 4 weeks ago - BioNTech Announces Fourth Quarter and Full Year 2023 Financial Results and Corporate Update - GlobeNewsWire
- 4 weeks ago - BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer - GlobeNewsWire